Evidence map›Paper›PMID 35677513›Full record

ArticleJournal of clinical and experimental hepatology

Correlation of Clinicopathological Profile, Prognostic Factors, and Survival Outcomes with Baseline Alfa-Fetoprotein Levels in Patients With Hepatocellular Carcinoma: A Biomarker that is Bruised but Not Broken.

Vaneet Jearth, Prachi S Patil, Shaesta Mehta, Sridhar Sundaram, Vishal Seth, Mahesh Goel, Shraddha Patkar, Munita Bal, Vidya Rao

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Vaneet JearthDepartment of Digestive Diseases and Clinical Nutrition, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
Prachi S PatilDepartment of Digestive Diseases and Clinical Nutrition, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
Shaesta MehtaDepartment of Digestive Diseases and Clinical Nutrition, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
Sridhar SundaramDepartment of Digestive Diseases and Clinical Nutrition, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
Vishal SethDepartment of Digestive Diseases and Clinical Nutrition, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
Mahesh GoelDivision of Hepatobiliary Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Shraddha PatkarDivision of Hepatobiliary Surgery, Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Munita BalDepartment of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
Vidya RaoDepartment of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute (HBNI), Mumbai, India.
Tata Memorial Hospital · INHomi Bhabha National Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: The role of Alfa-fetoprotein (AFP) in the management of hepatocellular carcinoma (HCC) is still debated, with differences in recommendations between international guidelines. We analyzed the relationship of the clinicopathological profile, prognostic features, and survival outcomes with baseline serum AFP levels in patients with HCC. Methods: Retrospective analysis of a prospectively accrued dataset of consecutive HCC patients was done. Results: 508 treatment naive patients were included in the analysis. AFP at presentation was normal (<10 ng/ml) in 18% patients. Patients with very high AFP (>400 ng/ml) had poor hepatic reserves (higher mean serum bilirubin, AST, ALT, INR, and lower mean albumin) and advanced disease at presentation (higher incidence of extrahepatic metastasis, and less proportion of patients with well-differentiated tumors). AFP >400 ng/ml was an independent predictor for presence of portal vein tumor thrombosis (PVTT) (OR, 4.08; 95% CI, 2.34-7.12; Conclusion: AFP as a biomarker still has a significant role to play in the management of HCC patients and is here to stay till the search for an ideal biomarker in HCC is over.

Indexed as

AFP, Alfa-fetoproteinalfa-fetoproteinBarcelona clinic liver cancer stagingBCLC, Barcelona clinic liver cancerbiomarkerBSC, Best supportive careEHM, Extrahepatic metastasisHBHC, HBV or HCV relatedHBV, Hepatitis B virusHCC, Hepatocellular carcinomaHCV, Hepatitis C virushepatocellular carcinomaMDT, Multidisciplinary teamMTD, Maximum tumor diameterNAFLD, Nonalcoholic fatty liver diseaseNBNC, Non B Non C relatedOS, Overall survivalportal vein tumor thrombosisPVTT, Portal vein tumor thrombosisRFA, Radiofrequency ablationSBRT, Stereotactic body radiation therapyTACE, Transarterial chemo-embolizationTARE, Transarterial radio-embolization

Identifiers

PMID35677513
PMCPMC9168719
OpenAlexW3211365788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.